yahoo_financeOriginal article
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
NDA FilingORPATHYSTAGRISSOPositive
AI Analysis
Summary
HUTCHMED announced submission of a US NDA for ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) for MET-driven EGFR-mutated lung cancer.
Outcome Details
Submission of US NDA for ORPATHYS plus TAGRISSO combination in MET-driven EGFR-mutated lung cancer
Importance:7/10
Sentiment:
0.60
NDA submissiononcologyNSCLCMETEGFRcombination therapy
Read the original article
Published by yahoo_finance on September 29, 2026 12:00 AM